AR420626 (0.1 mg/kg, i.p.; single dose) inhibits serotonin-induced defecation volume in male Sprague-Dawley rats[1].
AR420626 (0.1 mg/kg, i.p.; days 0-4; 0.2 mg/kg, i.p.; days 7-11) inhibits the growth of HepG2 xenografted male SHO nude mice[2].
AR420626 (0.1 mg/kg, i.p.; administered 30 minutes before modeling) inhibits the immune response in bronchoalveolar lavage fluid (BALF) and lung tissue of the allergic asthma model induced by ovalbumins (HY-W250978) in BALB/c mice; and inhibits the skin inflammatory immune response, cervical lymph node immune response and the development of eczema symptoms in the eczema model induced by 1-chloro-2, 4-dinitrobenzene (DNCB) in BALB/c mice[3].
AR420626 (13.32 and 26.64 μg/kg, i.p.; once a day for 7 days) at a dose of 26.64 μg/kg improves glucose tolerance by increasing plasma insulin levels and skeletal muscle glycogen content in male ICR mice with Streptozotocin (HY-13753) induced diabetes and C57BL/6 mice with high-fat diet-induced diabetes[4].
| Animal Model: | HepG2 xenograft model in male SHO nude mice [2] |
| Dosage: | 0.1 mg/kg on days 0-4 after tumors reach 500-1000 mm3
0.2 mg/kg on days 7-11 after tumors reach 500-1000 mm3 |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited the growth of HepG2 xenograft mice, and still had an inhibitory effect on the weight of mice after stopping administration. |
| Animal Model: | Ovalbumin (OVA)-induced asthma induction in BALB/c mice [3] |
| Dosage: | 0.1 mg/kg |
| Administration: | Intraperitoneal injection 30 min before OVA sensitization (D0 and D14) or 30 min before OVA challenge (D28, D29, and D30) |
| Result: | Suppressed the increased IL-4 and IL-17A levels.
Suppressed the increase in the number of eosinophils and total immune cells in bronchoalveolar lavage fluid (BALF).
Inhibited the increase of cytokine (IL-4, IL-13, IFN-γ and IL-17a) levels.
|
| Animal Model: | 1-chloro-2, 4-dinitrobenzene (DNCB)-induced eczema model in BALB/c mice[3] |
| Dosage: | 0.1 mg/kg |
| Administration: | Intraperitoneal injection 30 min before the DNCB challenge from day 19 |
| Result: | Reduced the number of accumulated immune cells and mast cells, inhibited acanthosis and epidermal thickening and mast cell accumulation, and inhibited IL-17A, TSLP and IL-8 levels.
Inhibited immune responses in the cervical lymph nodes, size enlargement, and expression of inflammatory cytokines and chemokines, but did not enhance the proportion of CD4+FoxP3+ Treg cells.
|
